Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-67571244 in Relapsed/Refractory AML and MDS
NCT03915379Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Mar 2022
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of JNJ-67571244 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability, Number of Participants with Dose-Limiting Toxicity (DLTs) up to 28 days and 2 more. Started Mar 2019; status: completed.
02
Drugs
JNJ-67571244
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03915379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915379.